Arovella Details Pre-Clinical Wins for Pancreatic and Gastric Cancer Therapy
Arovella Therapeutics (ASX: ALA) has presented pre-clinical data for its CLDN18.2-targeted CAR-iNKT cell therapy at the American Association for Cancer Research (AACR) Annual Meeting in San Diego. The poster presentation, titled “Allogeneic CAR-iNKT cell therapy targeting CLDN18.2-positive gastric and pancreatic cancers,” detailed findings first released on 1 April 2026, demonstrating tumour control across multiple cancer cell lines.
The AACR Annual Meeting serves as a major platform for visibility within the global cancer research community, attracting scientists, clinicians, and institutional investors focused on oncology innovation.
What is CLDN18.2 and why does it matter for cancer treatment?
CLDN18.2 (Claudin 18.2) is a tight junction protein normally sequestered between cells in healthy tissue, making it inaccessible to immune targeting. In normal physiology, CLDN18.2 expression is tightly restricted to gastric mucosal epithelial cells lining the gastrointestinal tract.
Malignant transformation in cancer cells leads to the exposure of CLDN18.2 on the cell surface, creating a targetable marker. This selectivity offers a favourable safety-efficacy balance, as the protein remains hidden in most healthy tissues but becomes accessible on tumour cells.
CLDN18.2 is prevalently expressed in gastric and pancreatic cancers, including both primary tumours and metastatic lesions. This expression profile makes it an attractive target for cell therapies designed to treat solid tumours with reduced off-tumour toxicity concerns.
Target selection is critical in cell therapy development. CLDN18.2’s restricted expression pattern in healthy tissue and consistent presence on cancer cells positions it as a viable candidate for therapies aiming to balance efficacy with safety.
When big ASX news breaks, our subscribers know first
Key findings from the pre-clinical data
The in vitro re-challenge studies demonstrated sustained tumour control across multiple cycles against both PaTu8988S pancreatic cancer cells and NUGC4-CLDN18.2 gastric cancer cells. Arovella’s IL-12-TM cytokine armouring technology enhanced CAR-iNKT cell expansion and functional activity.
| Finding | Detail |
|---|---|
| Tumour control | Effective control of pancreatic and gastric tumour cells across multiple re-challenge cycles |
| IL-12-TM effect on expansion | Enhanced CAR-iNKT cell expansion in presence of CLDN18.2+ targets |
| IFN-γ secretion | Significantly enhanced over multiple re-challenge cycles with IL-12-TM |
| CD62L expression | Upregulated with IL-12-TM inclusion — linked to improved persistence |
CAR-iNKT cells employ three killing mechanisms:
- Via the CAR (targeting CLDN18.2)
- Via the NKG2D pathway (recognising stress ligands upregulated on cancer cells)
- Via lipid-bound CD1d (naturally expressed by several cancer types)
Benefits of CD62L upregulation with IL-12-TM:
- Improved cell expansion
- Improved cell persistence
- Enhanced anti-tumour activity
Multiple re-challenge efficacy suggests durability potential, a key consideration for solid tumour therapies where sustained activity is required. The IL-12-TM technology differentiates Arovella’s approach from competing CAR-T platforms.
The IL-12-TM advantage
IL-12-TM is membrane-anchored rather than secreted, reducing systemic toxicity risk compared to exogenous IL-12 administration or untethered secretion. The tethered design allows IL-12-TM to stimulate CAR-iNKT cells in cis (self-stimulation) and in trans (stimulating other iNKT cells or endogenous immune cells).
This dual-mode stimulation supports both the engineered cell product and the patient’s native immune response, a strategic advantage in the solid tumour microenvironment where immune suppression often limits cell therapy efficacy.
Dr Michael Baker, CEO and Managing Director
“We are delighted to have been accepted to present our CLDN18.2-CAR-iNKT cell data at the AACR conference. It is exciting data and highlights the impressive performance of the CLDN18.2 CAR and the additional benefit of incorporating Arovella’s cytokine armouring technology, IL-12-TM.”
Arovella’s broader iNKT cell platform and pipeline progress
The CLDN18.2 programme sits within Arovella’s invariant Natural Killer T (iNKT) cell therapy platform, licensed from Imperial College London. The platform’s allogeneic (off-the-shelf) design allows administration from a healthy donor to a patient without the risk of graft-versus-host disease (GvHD), circumventing the need to knock out the endogenous T cell receptor (TCR).
Arovella’s lead programme, ALA-101, is a CD19-directed CAR-iNKT cell therapy for lymphomas and leukaemias. The product has secured IND acceptance from the US FDA and is progressing to Phase I clinical trials. The CLDN18.2 technology was licensed from Sparx Group.
Pipeline context:
- ALA-101: CD19-directed CAR-iNKT for lymphomas and leukaemias — IND accepted, progressing to Phase I
- ALA-105: CLDN18.2-directed CAR-iNKT with IL-12-TM for gastric and pancreatic cancers — pre-clinical
The platform approach allows Arovella to leverage validated manufacturing and technology across multiple programmes, potentially accelerating development timelines and reducing risk. Pre-clinical success in solid tumours could support expansion into additional targets beyond CLDN18.2.
The next major ASX story will hit our subscribers first
What comes next for Arovella’s solid tumour programme
Management indicated additional data generation is expected “in due course,” with no specific timeline provided for further readouts. The AACR presentation represents a milestone in building the scientific evidence base for ALA-105.
A video explanation from Dr Baker is available, and the poster is accessible on the company website at https://www.arovella.com.
Conference presentations often precede partnership discussions or further pre-clinical/clinical advancement. Investors should monitor for additional data readouts and potential IND-enabling study announcements that would position ALA-105 for clinical entry. The platform’s allogeneic nature and multi-tumour targeting capability may attract interest from larger oncology players seeking off-the-shelf cell therapy candidates.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Big News Blast alerts land in your inbox the moment market-moving announcements drop. Click the “Free Alerts” button to stay ahead on biotech news before the market reacts.